Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» T-DM1 Significantly Improved Progression-Free Survival Compared to Standard of Care for Previously Untreated HER2-Positive Metastatic Breast Cancer
T-DM1 Significantly Improved Progression-Free Survival Compared to Standard of Care for Previously Untreated HER2-Positive Metastatic Breast Cancer
T-DM1 Significantly Improved Progression-Free Survival Compared to Standard of Care for Previously Untreated HER2-Positive Metastatic Breast Cancer
Submitted by
admin
on September 25, 2011 - 12:57pm
Source:
Yahoo/GlobeNewswire
News Tags:
trastuzumab
T-DM1
breast cancer
Immunogen
Headline:
T-DM1 Significantly Improved Progression-Free Survival Compared to Standard of Care for Previously Untreated HER2-Positive Metastatic Breast Cancer
Do Not Allow Advertisers to Use My Personal information
